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A 55-year-old woman smoker with a history of cough,weight loss, and chest pain, without neurologic com-
plaints, presented with a mass in the right lung. A bronchos-
copy revealed a tumor in the right intermediate bronchus. The
biopsy of the lesion showed small cell carcinoma. A FDG-
positron emission tomography (PET)-computed tomography
(CT) scan was performed and is displayed in Figure 1A. A
brain CT was normal. After the diagnosis of limited-stage
small cell lung cancer, the patient was treated with four
cycles of cisplatin and etoposide combined with normo-
fractionated thoracic radiotherapy (55 Gy) concurrent with
the last two cycles. A radiological complete response was
assessed, and treatment was completed with prophylactic
cranial irradiation.
Seven months after complete response, the patient ex-
perienced rapidly progressive dizziness and gait instability,
followed by gaze disturbances and involuntary, continuous,
conjugate, and chaotic saccadic eye movements. The gait
disorder worsened, leaving the patient absolutely bedridden.
On examination, intermittent myoclonic movements were
apparent in the limbs and trunk (see video, part 1, Supple-
mental Digital Content 1, http://links.lww.com/JTO/A73,
which shows these findings). She had neither cognitive im-
pairment nor motor/sensory losses. Brain magnetic resonance
imaging and cerebrospinal fluid examination were without
noteworthy alterations. Serum antineuronal antibodies (anti-
Hu, anti-Ri, anti-CV2, and antiamphiphysin) were negative.
She was diagnosed with opsoclonus-myoclonus syndrome
(OMS), and intravenous corticoids were administered for 5
days without improvement. There was no evidence of relapse
on the chest CT, and the patient refused a bronchoscopy. A
positron emission tomography-CT examination was strictly
normal (Figure 1B). Although there was no visible tumor, we
considered OMS as its herald, and second-line chemotherapy
was started with carboplatin and etoposide in an attempt to
reverse her devastating neurologic condition. After just the
first cycle, opsoclonus and gait instability improved and the
myoclonus resolved completely (see video, part 2, Supple-
mental Digital Content 1, http://links.lww.com/JTO/A73,
which demonstrates her clinical improvement). The patient
has completed three cycles of chemotherapy and continued
free of recurrence for a total of 31 months, when a right
supraclavicular relapse was detected and pathologically con-
firmed. Nevertheless, paraneoplastic neurologic symptoms
did not recur, and third-line chemotherapy with oral topote-
can was started.
DISCUSSION
Most paraneoplastic neurologic syndromes are immune
mediated.1–3 The paraneoplastic syndromes involving the
nervous system typically precede the diagnosis of cancer, but
in a few instances, these disorders may follow the identifica-
tion and even the treatment of the tumor. As far as we know,
only two cases of OMS that first appear after the treatment
of small cell lung cancer have been reported,4,5 and conse-
quently information about its outcome is scarce. Paraneoplas-
tic OMS is a life-threatening condition, and the underlying
neoplasm must be promptly diagnosed and treated. OMS may
respond to treatment of the underlying tumor, immunosupres-
sion or both.
In this report, we emphasize the absence of identifiable
relapsing tumor at the onset of the OMS and the outcomes
after a short period of second-line chemotherapy. These were
a rapid, highly remarkable, long-lasting, and currently main-
tained neurologic response, and the appearance of detectable
tumor delayed for 31 months.
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FIGURE 1. Comparison between transaxial 18FDG-positron emission tomography (PET)/computed tomography (CT) images
at baseline and when the paraneoplastic neurologic syndrome began: A, increased uptake of 18FDG in right hilar mass and
mediastinal lymph nodes and (B) negative PET scan.
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